Normalizing naloxone as a first-aid tool and keeping information on sales of the opioid antagonist private are needed for expanding access and use in addition to OTC switch applications, according to emergency medicine and overdose prevention experts
Expanding Naloxone Access Needs Normalizing First-Aid Use, Keeping Purchase Records Private
Opposition to making naloxone available OTC remains strident because of stigma surrounding drug overdoses, says Bobby Mukkamala, a head and neck surgeon and an AMA Board of Trustees member.
More from Rx-to-OTC Switch
• By
HBW Insight speaks to AESGP director general Jurate Švarcaite about what's on the agenda for the upcoming 61st AESGP Annual Meeting, which will take place in Warsaw, Poland, between 2-4 June. Highlights include the role of prevention in self-care, discussions about how regulators will ensure the competitiveness of European industry on the world stage and incoming changes to sustainability legislation.
• By
“Overall, no unexpected/new data or findings” were presented to Germany's Expert Committee for Prescription in the most recent Rx-to-OTC switch application for sildenafil (25mg and 50mg), according to medicines regulator BfArM, resulting in a third rejection in three years.
• By
HBW Insight catches up with Maxwellia CEO Anna Maxwell to discuss her company's journey so far, and what she sees as the opportunities for Rx-to-OTC switch in UK women's health and beyond.
• By
Advercheck managing director James Walmsley talks to HBW Insight about the challenges facing consumer health companies today as they move away from the prescription medicines sector and its pipeline of switchable ingredients towards self-care and prevention.
More from Health
• By
FDA testing of 95 benzoyl peroxide products due to concerns about elevated benzene detected by third-party testers found 90% with undetectable or extremely low benzene levels.
• By
“Overall, no unexpected/new data or findings” were presented to Germany's Expert Committee for Prescription in the most recent Rx-to-OTC switch application for sildenafil (25mg and 50mg), according to medicines regulator BfArM, resulting in a third rejection in three years.
• By
Galenica outpaced the growth of the OTC market at home, while recording a double-digit gain abroad, to drive up its consumer health product sales in 2024.